HCA241220C430000
- 0.05
- 0.000.00%
HCA Healthcare Newsroom
Wells Fargo Downgrades HCA Healthcare(HCA.US) to Sell Rating, Cuts Target Price to $320
Wells Fargo Downgrades HCA Healthcare to Underweight From Equalweight, Adjusts Price Target to $320 From $400
HCA Healthcare Analyst Ratings
Raymond James Downgrades HCA Healthcare(HCA.US) to Hold Rating
BofA Securities Maintains HCA Healthcare(HCA.US) With Buy Rating
Barclays Maintains HCA Healthcare(HCA.US) With Buy Rating, Cuts Target Price to $392
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Moderna (MRNA) and HCA Healthcare (HCA)
HCA Healthcare Is Maintained at Equal-Weight by Wells Fargo
HCA Healthcare Analyst Ratings
Wells Fargo Maintains HCA Healthcare(HCA.US) With Hold Rating, Raises Target Price to $400
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
Cantor Fitzgerald Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $405
HCA Healthcare Price Target Cut to $440.00/Share From $450.00 by TD Cowen
Leerink Partners Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $460
Oppenheimer Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $400
A Quick Look at Today's Ratings for HCA Healthcare(HCA.US), With a Forecast Between $396 to $460
HCA Healthcare Is Maintained at Outperform by Oppenheimer
HCA Healthcare Analyst Ratings
Leerink Partners Adjusts HCA Healthcare's Price Target to $460 From $465, Keeps Outperform Rating
HCA Healthcare (HCA) Gets a Buy From RBC Capital